Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma.

Abstract

We report a case with a complete pathology-proven remission after sunitinib treatment of a relapsed irresectable clear cell renal carcinoma. A significant objective response was observed with tumor size reduction during treatment. After surgery, on pathologic examination it was concluded that the patient exhibited a complete response; activity and the feasibility and safety of subsequent surgical resection were assessed. Otherwise after discontinuing sunitinib, the patient had a relapse on the same location; sunitinib has been resumed and was again found to be effective.

• Authors: Maria Angeles Vaz, Vanessa Pachón, Enrique Grande, Reyes Ferreiro, Alfredo Carrato
• Journal: Anti-cancer drugs (Anticancer Drugs) Vol. 22 Issue 8 Pg. 817-21 (Sep 2011) ISSN: 1473-5741 [Electronic] England
• PMID: 21566523 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Indoles
• Pyrroles
• Sunitinib

Topics

• Antineoplastic Agents (therapeutic use)
• Carcinoma, Renal Cell (drug therapy, pathology, surgery)
• Combined Modality Therapy
• Humans
• Indoles (therapeutic use)
• Kidney Neoplasms (drug therapy, pathology, surgery)
• Male
• Middle Aged
• Neoplasm Recurrence, Local
• Pyrroles (therapeutic use)
• Remission Induction (methods)
• Sunitinib
• Treatment Outcome